{"count": 4, "results": [{"_id": "35875417", "pmid": 35875417, "pmcid": "PMC9297462", "title": "Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma", "journal": "Clin Med Insights Oncol", "authors": ["Jing CY", "Li SN", "Shan BE", "Zhang W", "Tian WJ", "Ren YL", "Wang HY"], "date": "2022-07-18T00:00:00Z", "doi": "10.1177/11795549221110522", "meta_date_publication": "2022", "meta_volume": "16", "meta_issue": "", "meta_pages": "11795549221110522", "score": 50266.41, "text_hl": "Hysteroscopic Curettage Followed by @CHEMICAL_Megestrol_Acetate @CHEMICAL_MESH:D019290 @@@Megestrol Acetate@@@ Plus @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as a Fertility-Sparing Treatment for @SPECIES_9606 @@@Women@@@ with Atypical @DISEASE_Endometrial_Hyperplasia @DISEASE_MESH:D004714 @@@Endometrial Hyperplasia@@@ or Well-Differentiated @<m>DISEASE_Carcinoma_Endometrioid</m> @DISEASE_MESH:D018269 @@@Endometrioid Endometrial Carcinoma@@@", "citations": {"NLM": "Jing CY, Li SN, Shan BE, Zhang W, Tian WJ, Ren YL, Wang HY. Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma Clin Med Insights Oncol. 2022;16():11795549221110522. PMID: 35875417", "BibTeX": "@article{35875417, title={Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma}, author={Jing CY and Li SN and Shan BE and Zhang W and Tian WJ and Ren YL and Wang HY}, journal={Clin Med Insights Oncol}, volume={16}, pages={11795549221110522}}"}}, {"_id": "37364543", "pmid": 37364543, "title": "Curative polyendocrine therapy in a 21 year old patient with endometrial carcinoma. Case report and review of literature.", "journal": "Oncol Res Treat", "authors": ["Schäffler H", "Dimpfl M", "Schochter F", "Janni W", "de Gregorio N"], "date": "2023-06-26T00:00:00Z", "doi": "10.1159/000531661", "meta_date_publication": "2023 Jun 26", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50243.168, "text_hl": "A control dilation and curettage (D&C) after 4 months revealed early-stage, well-differentiated @<m>DISEASE_Carcinoma_Endometrioid</m> @DISEASE_MESH:D018269 @@@endometrioid endometrial carcinoma@@@. ", "citations": {"NLM": "Schäffler H, Dimpfl M, Schochter F, Janni W, de Gregorio N. Curative polyendocrine therapy in a 21 year old patient with endometrial carcinoma. Case report and review of literature. Oncol Res Treat. 2023 Jun 26;():. PMID: 37364543", "BibTeX": "@article{37364543, title={Curative polyendocrine therapy in a 21 year old patient with endometrial carcinoma. Case report and review of literature.}, author={Schäffler H and Dimpfl M and Schochter F and Janni W and de Gregorio N}, journal={Oncol Res Treat}}"}}, {"_id": "26312913", "pmid": 26312913, "title": "A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.", "journal": "Lancet", "authors": ["Sivalingam V", "McVey R", "Gilmour K", "Ali S", "Roberts C", "Renehan A", "Kitchener H", "Crosbie E"], "date": "2015-02-26T00:00:00Z", "doi": "10.1016/S0140-6736(15)60405-6", "meta_date_publication": "2015 Feb 26", "meta_volume": "385 Suppl 1", "meta_issue": "", "meta_pages": "S90", "score": 50054.605, "text_hl": "We tested the hypothesis that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ would reduce cellular proliferation in vivo in @DISEASE_Endometrial_Hyperplasia @DISEASE_MESH:D004714 @@@atypical endometrial hyperplasia@@@ and @<m>DISEASE_Carcinoma_Endometrioid</m> @DISEASE_MESH:D018269 @@@endometrial endometrioid adenocarcinoma@@@. ", "citations": {"NLM": "Sivalingam V, McVey R, Gilmour K, Ali S, Roberts C, Renehan A, Kitchener H, Crosbie E. A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. Lancet. 2015 Feb 26;385 Suppl 1():S90. PMID: 26312913", "BibTeX": "@article{26312913, title={A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.}, author={Sivalingam V and McVey R and Gilmour K and Ali S and Roberts C and Renehan A and Kitchener H and Crosbie E}, journal={Lancet}, volume={385 Suppl 1}, pages={S90}}"}}, {"_id": "24972190", "pmid": 24972190, "title": "Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.", "journal": "Gynecol Oncol", "authors": ["Laskov I", "Drudi L", "Beauchamp MC", "Yasmeen A", "Ferenczy A", "Pollak M", "Gotlieb WH"], "date": "2014-09-01T00:00:00Z", "doi": "10.1016/j.ygyno.2014.06.014", "meta_date_publication": "2014 Sep", "meta_volume": "134", "meta_issue": "3", "meta_pages": "607-14", "score": 50053.152, "text_hl": "RESULTS: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ was administered for a mean of 36.6 days. ", "citations": {"NLM": "Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol. 2014 Sep;134(3):607-14. PMID: 24972190", "BibTeX": "@article{24972190, title={Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.}, author={Laskov I and Drudi L and Beauchamp MC and Yasmeen A and Ferenczy A and Pollak M and Gotlieb WH}, journal={Gynecol Oncol}, volume={134}, number={3}, pages={607-14}}"}}]}